Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.46 |
| ▸ | CPS1 | P31327 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113759 | 0.84 | MAPT (0.61) | KDM2BCPS1MAPTKDM4EHPGD | |
| SCHEMBL4115692 | 0.84 | KDM2B (0.47) | POLBKDM2BCPS1MAPTKDM4E | |
| SCHEMBL7423445 | 0.81 | KDM2B (0.50) | POLBKDM2BCPS1MAPTKDM4E | |
| SCHEMBL4839335 | 0.81 | KDM2B (0.50) | POLBKDM2BCPS1MAPTKDM4E | |
| SCHEMBL1340897 | 0.81 | NOS2 (0.48) | POLBKDM2BCPS1MAPTKDM4E | |
| SCHEMBL30514010 | 0.79 | CPS1 (0.70) | KDM2BCPS1MEN1KMT2A | |
| SCHEMBL1942608 | 0.79 | CPS1 (0.70) | KDM2BCPS1MEN1KMT2A | |
| SCHEMBL5280460 | 0.79 | KDM2B (0.49) | KDM2BCPS1MAPTKDM4EMEN1 | |
| SCHEMBL4129937 | 0.78 | MAPT (0.55) | KDM2BCPS1MAPTKDM4EHPGD | |
| SCHEMBL14477305 | 0.78 | KDM2B (0.50) | KDM2BCPS1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145364-B2 | Synthesis of psuedo indoxyl derivatives | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-09-29 | — | — | US | disclosed |
| US-20140309434-A1 | SYNTHESIS OF PSUEDO INDOXYL DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309434-A1 | SYNTHESIS OF PSUEDO INDOXYL DERIVATIVES | IPO4, IPO11, IDO2 | POLB 2683/4885KDM2B 1879/4885CPS1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.